Clinical Trial Update: Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Ebola Virus Vaccine (rVSVΔG-ZEBOV-GP) [Phase 1]

View source ↗

Summary

Phase I trial evaluating the safety, tolerability, and immunogenicity of the Ebola vaccine rVSVΔG-ZEBOV-GP.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebola Virus Disease

Drugs mentioned

• rVSVΔG-ZEBOV-GP

Snippet

Sponsor: Universitätsklinikum Hamburg-Eppendorf | Conditions: Hemorrhagic Fever, Ebola | Phase 1 | Status: COMPLETED